A Chemically Induced CRISPR/dCas13<sup>FCPF</sup> Platform for Precise and Programmable RNA Regulation. [PDF]
Hasselbeck S +6 more
europepmc +1 more source
Efficacy and safety of risdiplam in adults with 5q-associated spinal muscular atrophy: a nationwide observational cohort study in Austria. [PDF]
Keritam O +34 more
europepmc +1 more source
Swallowing and feeding after disease-modifying treatment for spinal muscular atrophy: a systematic review of assessment modalities and outcomes. [PDF]
Martí Y +6 more
europepmc +1 more source
Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment [PDF]
Boido, Marina Maria +3 more
core +1 more source
Analyse der gesundheitsbezogenen Lebensqualität von Patienten mit spinaler Muskelatrophie (SMA) unter der Therapie mit Nusinersen und Ermittlung der Belastung ihrer pflegenden Angehörigen [PDF]
Velling, Ann-Kathrin
core +1 more source
Newborn Screening for Spinal Muscular Atrophy in the UK: Use of Modelling to Identify Priorities for Ongoing Evaluation. [PDF]
Thokala P +6 more
europepmc +1 more source
Five-year disease-modifying therapeutic experience of 102 Chinese paediatric 5q-spinal muscular atrophy: a retrospective analysis. [PDF]
Jiang M +12 more
europepmc +1 more source
Pregnancy in women with spinal muscular atrophy (SMA): maternal and neonatal outcomes with multi-speciality management. [PDF]
Cohen D +5 more
europepmc +1 more source
Disease characteristics and treatment status of genetically confirmed spinal muscular atrophy patients: a cross-sectional survey in China. [PDF]
Zhang D +5 more
europepmc +1 more source

